Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Biodesix, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on May 19, 2026 at 1:00 p.m. Mountain Time. Stockholders of record on March 23, 2026, when 10,107,219 common shares were outstanding, may vote online on four key proposals.
These proposals are the election of two Class III directors to serve until 2029, a non-binding advisory vote on 2025 compensation for named executive officers, an advisory vote on how often to hold future say‑on‑pay votes (the board recommends every one year), and ratification of KPMG LLP as independent auditor for 2026.
The proxy also outlines Biodesix’s board structure, committee membership, director and executive pay (including 2025 salary increases, cash bonuses and equity awards) and new severance and change‑in‑control agreements for senior executives, together with stock ownership, equity plan data and pay‑versus‑performance disclosures.
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026. He converted 1,361 RSUs into 1,361 shares of common stock at an exercise price of $0.00 per share. Following the transactions, he directly holds 24,022 common shares and 4,082 RSUs, with additional indirect holdings through Patience Enterprises LP, the John Patience Living Trust, and his spouse.
Biodesix, Inc. reports strong 2025 growth as a lung‑focused diagnostics company. The business generated an estimated $88.5 million in total revenue, up 24% from 2024, driven mainly by its Biodesix Lung Diagnostic Testing segment.
Lung Diagnostic Testing produced $79.2 million of revenue from about 62,600 tests, increases of 22% and 15%, while Development Services contributed $9.3 million, up 41%. Gross margin improved to 81% from 78% as the company emphasized operational efficiencies and cost discipline, limiting operating expense growth (excluding direct costs and expenses) to 10% while revenue rose 24%.
Biodesix offers five blood‑based lung tests spanning nodule diagnosis, treatment guidance and monitoring, and estimates over 10 million annual testing opportunities in the U.S. representing a market of more than $27 billion. The company highlights expanding clinical data, growing reimbursement coverage, and multiple ongoing clinical studies, while operating CLIA‑certified, CAP‑accredited laboratories and maintaining an extensive intellectual property portfolio.
Biodesix reported strong fourth-quarter and full-year 2025 results, highlighted by rapid growth and improving profitability metrics. Q4 revenue reached $28.8 million, up 41%, with gross margin expanding to 83%. For 2025, total revenue was $88.5 million and gross margin was 81%, reflecting operating scale in its lung-focused diagnostics and development services businesses.
Net loss narrowed to $4.0 million in Q4 and $35.3 million for 2025, while Adjusted EBITDA turned positive at $0.5 million in Q4 and improved to a $17.5 million loss for the year. The company ended 2025 with $19.0 million in cash and subsequently raised an additional $14.7 million and extended its senior term loan maturity to November 2028. For 2026, Biodesix guides revenue between $106 million and $112 million, with the midpoint implying about 23% growth and continued progress toward sustained Adjusted EBITDA profitability.
Biodesix Chief Development Officer Gary Anthony Pestano reported RSU vesting and a related tax sale. On February 20, 1,528 Restricted Stock Units were exercised into 1,528 shares of Biodesix common stock at $0.00 per share, as part of an annual vesting schedule starting February 20, 2025.
On February 23, 556 shares of common stock were sold at a weighted average price of $12.7756 per share by the issuer's broker to cover taxes due upon RSU vesting for certain employees, including Pestano. After these transactions, Pestano directly held 10,359 shares of common stock and 4,582 RSUs, which continue to vest in four equal annual installments.
Biodesix Inc.'s Chief Commercial Officer Kieran O'Kane reported insider transactions involving common stock and restricted stock units. On February 23, 2026, he sold 535 shares of common stock in an open-market transaction at a weighted average price of $12.7756 per share to cover taxes upon the vesting of restricted stock units. These shares were sold by the issuer's broker in multiple trades between $12.58 and $13.16 per share. On February 20, 2026, 1,469 restricted stock units were exercised and converted into 1,469 shares of common stock at $0.00 per share. Following these transactions, O'Kane held 9,819 shares of common stock and 4,406 restricted stock units, after adjustments for a one-for-twenty reverse stock split effective September 15, 2025. The RSUs vest in four equal annual installments starting February 20, 2025, generally conditioned on continued service.
Biodesix Inc (BDSX) CFO Robin Harper Cowie reported routine equity award activity and a small tax-related share sale. On February 20, 2026, 1,469 restricted stock units were exercised into 1,469 shares of common stock at a price of $0.00 per share, increasing directly held common stock to 16,766 shares.
On February 23, 2026, Cowie sold 535 shares of common stock in an open‑market transaction at a weighted average price of $12.7756 per share, leaving 16,231 common shares directly owned. Footnotes state these shares were sold automatically by the issuer’s broker to cover taxes upon RSU vesting, in multiple trades ranging from $12.58 to $13.16 per share.
Each RSU represents a right to receive one share of common stock, and the RSUs vest in four equal annual installments beginning February 20, 2025, generally subject to continued service. The holdings and award numbers reflect a one‑for‑twenty reverse stock split effective September 15, 2025.
Biodesix Inc Chief Accounting Officer Chris Vazquez reported equity transactions involving restricted stock units (RSUs) and common stock. On February 20, 2026, RSUs covering 563 shares were exercised for no cash cost, converting into the same number of common shares. Following this, on February 23, 2026, 211 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share to cover taxes due upon RSU vesting, with individual sale prices ranging from $12.58 to $13.16. After these transactions, Vazquez directly held 1,586 common shares and 1,689 RSUs, with the RSUs scheduled to vest in four equal annual installments starting February 20, 2025.
Biodesix Inc. President & CEO Scott Hutton reported equity transactions involving company stock and restricted stock units. On February 20, 2026, 4,844 restricted stock units were exercised into 4,844 shares of common stock at $0.00 per share, increasing his direct common share holdings to 50,257 and leaving 14,531 RSUs outstanding. On February 23, 2026, 1,490 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share, in a price range from $12.58 to $13.16, with the sale made automatically by the issuer’s broker to cover taxes upon RSU vesting. Following these transactions, he directly owned 48,767 shares of Biodesix common stock.